Just added shares to both my IRA and Roth accounts this am. The two recent down weeks in the chart while holding the 10-week moving average suggest a potential upward trend. Chart showing higher lows and hopefully higher highs coming. 🍀🐂
Im at a crossroad with this position. I have been holding since 2020, it started off as a very small position in my portfolio but has now past all of my other stock picks, to the point that it is the majority of my portfolio (40%). On one hand nothing about my thesis has changed, I still believe in the company, if anything more than ever, and I don't necessarily need the money right now, it would probably be reinvested into another sector. On the other hand I'm not sure how to feel about it being this big of a portion of my portfolio, I usually try to stay a bit more diversified but can't help but feel I'd be missing out on possible gains if I sold any time soon with the amount of attention this one has been getting. Just curious how you guys are all feeling about the stock at this current price?
Psychiatry is at an inflection point. And the stakes are high. Mental illness costs the U.S. economy more than $280 billion annually, drives veteran suicide rates, and places mounting strain on everything from emergency rooms to the workforce. Yet many of today’s medicines have not advanced in decades despite the rising prevalence and unmet need. For the one in five Americans living with a mental health disorder and veterans who face disproportionally high suicide rates and do not respond to conventional treatments, the gap between what medicine promises and what it delivers has never been more consequential. But change is underway. A new wave of rigorous clinical science is unlocking the therapeutic potential of psychedelic medicines and opening new routes for brain health that could redefine what treatment success looks like. Psychedelic medicines are advancing through late-stage clinical trials, with several investigational candidates earning FDA Breakthrough Therapy Designation for disorders including anxiety and depression. Join The Hill, in partnership with Definium Therapeutics, for a timely mental health policy forum convening lawmakers, clinical researchers, and advocates to explore what science tells us, what the regulatory landscape requires, and what actions Congress can take to ensure that patients are not left behind.